MGNX
MacroGenics, Inc.
MGNX
(2.0)3,30 USD
14.58% ROA
-5.77% ROE
13.44x PER
666.816.050,00 USD
17.58% DER
0% Yield
-15.42% NPM
MacroGenics, Inc. Stock Analysis
MacroGenics, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a minimal amount of debt (20%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 2 |
ROE
ROE in an average range (5.39%) suggests satisfactory profitability and decent utilization of shareholders' equity. |
|
| 3 |
ROA
The stock's ROA (2.41%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits. |
|
| 4 |
PBV
The stock's PBV ratio (2.74x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns. |
|
| 5 |
Revenue Growth
This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment. |
|
| 6 |
Net Profit Growth
This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity. |
|
| 7 |
Buffet Intrinsic Value
Based on Warren Buffett's formula, the company's stock appears undervalued (84), presenting an attractive investment chance with its intrinsic value surpassing the current market price. |
|
| 8 |
Assets Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 9 |
Graham Number
The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity. |
|
| 10 |
Dividend Growth
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns. |
|
| 11 |
Dividend
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments. |
MacroGenics, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
MacroGenics, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2011 | 47.054.397 | |
| 2012 | 59.645.819 | 21.11% |
| 2013 | 56.753.123 | -5.1% |
| 2014 | 47.264.000 | -20.08% |
| 2015 | 100.854.000 | 53.14% |
| 2016 | 86.582.000 | -16.48% |
| 2017 | 155.516.000 | 44.33% |
| 2018 | 60.121.000 | -158.67% |
| 2019 | 62.024.000 | 3.07% |
| 2020 | 97.764.000 | 36.56% |
| 2021 | 75.643.000 | -29.24% |
| 2022 | 151.941.000 | 50.22% |
| 2023 | 41.588.000 | -265.35% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2011 | 41.088.899 | |
| 2012 | 45.432.894 | 9.56% |
| 2013 | 46.581.930 | 2.47% |
| 2014 | 70.186.000 | 33.63% |
| 2015 | 98.271.000 | 28.58% |
| 2016 | 122.091.000 | 19.51% |
| 2017 | 147.232.000 | 17.08% |
| 2018 | 190.827.000 | 22.85% |
| 2019 | 195.309.000 | 2.29% |
| 2020 | 193.201.000 | -1.09% |
| 2021 | 214.577.000 | 9.96% |
| 2022 | 207.026.000 | -3.65% |
| 2023 | 120.524.000 | -71.77% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2011 | 10.868.791 | |
| 2012 | 10.187.894 | -6.68% |
| 2013 | 11.086.759 | 8.11% |
| 2014 | 15.926.000 | 30.39% |
| 2015 | 22.765.000 | 30.04% |
| 2016 | 29.831.000 | 23.69% |
| 2017 | 32.653.000 | 8.64% |
| 2018 | 40.500.000 | 19.38% |
| 2019 | 46.064.000 | 12.08% |
| 2020 | 42.742.000 | -7.77% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2011 | 6.396.976 | |
| 2012 | 9.165.240 | 30.2% |
| 2013 | 1.559.319 | -487.77% |
| 2014 | -38.315.000 | 104.07% |
| 2015 | -17.319.000 | -121.23% |
| 2016 | -60.042.000 | 71.16% |
| 2017 | -22.143.000 | -171.16% |
| 2018 | -162.927.000 | 86.41% |
| 2019 | -166.340.000 | 2.05% |
| 2020 | -131.060.000 | -26.92% |
| 2021 | -202.795.000 | 35.37% |
| 2022 | -121.418.000 | -67.02% |
| 2023 | -142.008.000 | 14.5% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2011 | 47.054.397 | |
| 2012 | 59.645.819 | 21.11% |
| 2013 | 56.753.123 | -5.1% |
| 2014 | 47.264.000 | -20.08% |
| 2015 | 100.854.000 | 53.14% |
| 2016 | 86.582.000 | -16.48% |
| 2017 | 155.516.000 | 44.33% |
| 2018 | 60.121.000 | -158.67% |
| 2019 | 62.024.000 | 3.07% |
| 2020 | 97.764.000 | 36.56% |
| 2021 | 72.992.000 | -33.94% |
| 2022 | 144.557.000 | 49.51% |
| 2023 | 41.248.000 | -250.46% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2011 | 6.717.120 | |
| 2012 | 8.361.755 | 19.67% |
| 2013 | -260.835 | 3305.76% |
| 2014 | -38.313.000 | 99.32% |
| 2015 | -20.140.000 | -90.23% |
| 2016 | -58.528.000 | 65.59% |
| 2017 | -19.626.000 | -198.22% |
| 2018 | -171.453.000 | 88.55% |
| 2019 | -151.811.000 | -12.94% |
| 2020 | -117.782.000 | -28.89% |
| 2021 | -190.857.000 | 38.29% |
| 2022 | -120.021.000 | -59.02% |
| 2023 | 70.216.000 | 270.93% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2011 | 0 | |
| 2012 | 0 | 0% |
| 2013 | 0 | 0% |
| 2014 | -1 | 100% |
| 2015 | -1 | 0% |
| 2016 | -2 | 100% |
| 2017 | -1 | 0% |
| 2018 | -4 | 100% |
| 2019 | -3 | -33.33% |
| 2020 | -2 | -50% |
| 2021 | -3 | 33.33% |
| 2022 | -2 | -200% |
| 2023 | 1 | 200% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2011 | 6.257.127 | |
| 2012 | -7.522.032 | 183.18% |
| 2013 | -17.132.899 | 56.1% |
| 2014 | -36.331.000 | 52.84% |
| 2015 | -22.858.000 | -58.94% |
| 2016 | -55.060.000 | 58.49% |
| 2017 | -14.998.000 | -267.12% |
| 2018 | -178.188.000 | 91.58% |
| 2019 | -138.559.000 | -28.6% |
| 2020 | -117.804.000 | -17.62% |
| 2021 | -150.031.000 | 21.48% |
| 2022 | -90.582.000 | -65.63% |
| 2023 | -35.745.000 | -153.41% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2011 | 6.757.340 | |
| 2012 | -6.581.989 | 202.66% |
| 2013 | -14.172.123 | 53.56% |
| 2014 | -32.759.000 | 56.74% |
| 2015 | -13.661.000 | -139.8% |
| 2016 | -43.679.000 | 68.72% |
| 2017 | 14.405.000 | 403.22% |
| 2018 | -153.234.000 | 109.4% |
| 2019 | -134.270.000 | -14.12% |
| 2020 | -111.898.000 | -19.99% |
| 2021 | -143.830.000 | 22.2% |
| 2022 | -86.959.000 | -65.4% |
| 2023 | -35.246.000 | -146.72% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2011 | 500.213 | |
| 2012 | 940.043 | 46.79% |
| 2013 | 2.960.776 | 68.25% |
| 2014 | 3.572.000 | 17.11% |
| 2015 | 9.197.000 | 61.16% |
| 2016 | 11.381.000 | 19.19% |
| 2017 | 29.403.000 | 61.29% |
| 2018 | 24.954.000 | -17.83% |
| 2019 | 4.289.000 | -481.81% |
| 2020 | 5.906.000 | 27.38% |
| 2021 | 6.201.000 | 4.76% |
| 2022 | 3.623.000 | -71.16% |
| 2023 | 499.000 | -626.05% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2011 | -17.484.284 | |
| 2012 | -8.237.308 | -112.26% |
| 2013 | 78.914.468 | 110.44% |
| 2014 | 121.286.000 | 34.94% |
| 2015 | 313.337.000 | 61.29% |
| 2016 | 268.751.000 | -16.59% |
| 2017 | 299.238.000 | 10.19% |
| 2018 | 242.877.000 | -23.21% |
| 2019 | 230.628.000 | -5.31% |
| 2020 | 295.884.000 | 22.05% |
| 2021 | 239.618.000 | -23.48% |
| 2022 | 142.013.000 | -68.73% |
| 2023 | 193.980.000 | 26.79% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2011 | 62.680.584 | |
| 2012 | 53.746.900 | -16.62% |
| 2013 | 125.782.381 | 57.27% |
| 2014 | 173.886.000 | 27.66% |
| 2015 | 359.269.000 | 51.6% |
| 2016 | 311.263.000 | -15.42% |
| 2017 | 373.883.000 | 16.75% |
| 2018 | 332.130.000 | -12.57% |
| 2019 | 312.501.000 | -6.28% |
| 2020 | 378.743.000 | 17.49% |
| 2021 | 335.245.000 | -12.97% |
| 2022 | 280.468.000 | -19.53% |
| 2023 | 339.972.000 | 17.5% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2011 | 80.164.868 | |
| 2012 | 61.984.208 | -29.33% |
| 2013 | 46.867.913 | -32.25% |
| 2014 | 52.600.000 | 10.9% |
| 2015 | 45.932.000 | -14.52% |
| 2016 | 42.512.000 | -8.04% |
| 2017 | 74.645.000 | 43.05% |
| 2018 | 89.253.000 | 16.37% |
| 2019 | 81.873.000 | -9.01% |
| 2020 | 82.859.000 | 1.19% |
| 2021 | 95.627.000 | 13.35% |
| 2022 | 138.455.000 | 30.93% |
| 2023 | 145.992.000 | 5.16% |
MacroGenics, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 1.92
- Net Income per Share
- 0.8
- Price to Earning Ratio
- 13.44x
- Price To Sales Ratio
- 5.61x
- POCF Ratio
- -31.96
- PFCF Ratio
- -29.79
- Price to Book Ratio
- 3.43
- EV to Sales
- 5.14
- EV Over EBITDA
- 1015
- EV to Operating CashFlow
- -29.31
- EV to FreeCashFlow
- -27.3
- Earnings Yield
- 0.07
- FreeCashFlow Yield
- -0.03
- Market Cap
- 0,67 Bil.
- Enterprise Value
- 0,61 Bil.
- Graham Number
- 7.51
- Graham NetNet
- 2.1
Income Statement Metrics
- Net Income per Share
- 0.8
- Income Quality
- -0.42
- ROE
- 0.32
- Return On Assets
- -0.03
- Return On Capital Employed
- -0.69
- Net Income per EBT
- 1
- EBT Per Ebit
- 0.05
- Ebit per Revenue
- -2.86
- Effective Tax Rate
- 0
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 1.39
- Stock Based Compensation to Revenue
- 0.16
- Gross Profit Margin
- 0.99
- Operating Profit Margin
- -2.86
- Pretax Profit Margin
- -0.15
- Net Profit Margin
- -0.15
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -0.34
- Free CashFlow per Share
- -0.36
- Capex to Operating CashFlow
- 0.07
- Capex to Revenue
- -0.01
- Capex to Depreciation
- -0.14
- Return on Invested Capital
- -0.44
- Return on Tangible Assets
- 0.15
- Days Sales Outstanding
- 77.69
- Days Payables Outstanding
- 183.33
- Days of Inventory on Hand
- 59.17
- Receivables Turnover
- 4.7
- Payables Turnover
- 1.99
- Inventory Turnover
- 6.17
- Capex per Share
- -0.02
Balance Sheet
- Cash per Share
- 4,14
- Book Value per Share
- 3,13
- Tangible Book Value per Share
- 3.13
- Shareholders Equity per Share
- 3.13
- Interest Debt per Share
- 0.57
- Debt to Equity
- 0.18
- Debt to Assets
- 0.1
- Net Debt to EBITDA
- -92.67
- Current Ratio
- 5.68
- Tangible Asset Value
- 0,19 Bil.
- Net Current Asset Value
- 0,15 Bil.
- Invested Capital
- 0.18
- Working Capital
- 0,24 Bil.
- Intangibles to Total Assets
- 0
- Average Receivables
- 0,02 Bil.
- Average Payables
- 0,00 Bil.
- Average Inventory
- 1254500
- Debt to Market Cap
- 0.05
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
MacroGenics, Inc. Profile
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
- CEO
- Dr. Scott Koenig M.D., Ph.D.
- Employee
- 357
- Address
-
9704 Medical Center Drive
Rockville, 20850
MacroGenics, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Dr. Christopher Shayne James M.D. Vice President of Investor Relations & Corporation Communications |
70 |
| 2 |
Mr. James Karrels Senior Vice President, Chief Financial Officer & Corporate Secretary |
70 |
| 3 |
Dr. Stephen L. Eck M.D., Ph.D. Senior Vice President of Clinical Development & Chief Medical Officer |
70 |
| 4 |
Dr. Scott Koenig M.D., Ph.D. President, Chief Executive Officer & Director |
70 |
| 5 |
Mr. Eric Blasius Risser Chief Operating Officer |
70 |
| 6 |
Dr. Thomas M. Spitznagel Ph.D. Senior Vice President of Technical Operations |
70 |
| 7 |
Dr. Ezio Bonvini Senior Vice President of Research & Chief Scientific Officer |
70 |
| 8 |
Ms. Lynn Cilinski Vice President, Controller & Treasurer |
70 |
MacroGenics, Inc. Competitors
